Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on Kymera Therapeutics (NASDAQ:KYMR) in the last three months.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 1 | 2 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 1 | 1 | 0 | 0 |
| 3M Ago | 2 | 0 | 0 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $44.0, along with a high estimate of $52.00 and a low estimate of $36.00. This upward trend is apparent, with the current average reflecting a 5.19% increase from the previous average price target of $41.83.
Breaking Down Analyst Ratings: A Detailed Examination
The...
ログインすると全部閲覧できます。
ログイン